The uniform sale pattern across all directors is consistent with a pre-arranged 10b5-1 plan or tax-withholding event tied to vesting, not a coordinated bearish signal. No C-suite participation and the minuscule dollar amount relative to market cap make this a non-event for traders. Monitor for any subsequent Form 4 filings that clarify the plan structure, but no immediate action warranted.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 4 $17.99entry
- T+1 · 6mo ago −4.61%α −2.04% · $17.16
- T+5 · 5mo ago −1.56%α +1.00% · $17.71
- T+20 · 4mo ago −4.39%α −3.02% · $17.20
- T+60 · 3mo ago −0.94%α −2.83% · $17.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven NovoCure directors sold identical blocks of 2,945 shares each at $15.77 on June 2, 2026, totaling $325K in open-market sales. The uniform size and timing strongly suggest a coordinated sale, likely tied to a pre-arranged plan or tax-related event rather than opportunistic bearish conviction. Two directors also received non-cash stock grants on June 3, further supporting a routine compensation/planning context. At $2.1B market cap, the $325K represents just 0.015% of market cap, well below the 0.1% materiality threshold.
Key Financial Metrics
Key Facts
- Seven directors each sold exactly 2,945 shares at $15.7707 on June 2, 2026, identical size and price point across all sellers
- Total open-market sale value: $325,112.98 (0.015% of $2.1B market cap)
- Two directors (Vernon W. Anthony and Martin J. Madden) received non-cash stock grants totaling 28,609 shares on June 3, 2026
- No C-suite executives (CEO, CFO, COO) participated in the sales, only board members
- Recent 30-day insider activity shows 6 prior sells totaling $279K, suggesting ongoing routine portfolio management
Financial Impact
Total sales of $325K represent 0.015% of market cap, economically trivial
Risk Factors
- If the sales were not pre-arranged, the unanimity could indicate a shared negative view, but the trivial size makes this unlikely to be material
- The stock grants on June 3 could trigger additional selling to cover taxes, but amounts remain small
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NVCR-1780691177500 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers